Private Label Tranexamic Acid Niacinamide Eye Serum

The minimum order quantity for a private label tranexamic acid niacinamide eye serum depends primarily on whether you choose a stock formula or invest in custom development. For stock or white-label bases — formulas the manufacturer already has stability-tested and ready to fill — MOQs typically start at 100 to 300 units. These are the most accessible entry points for indie founders testing a new SKU or launching their first product. The trade-off is limited differentiation: you may be able to adjust fragrance, preservative type, or packaging, but the core active percentages and base formula are fixed. Semi-custom routes, where a cosmetic chemist modifies a proven base to hit your target TXA and niacinamide concentrations, generally carry MOQs of 300 to 500 units. This is the sweet spot for most indie brands — you get meaningful differentiation without the cost and timeline of full custom development. Fully custom formulas, developed from scratch to your brief, almost always require 500 to 2,000 units for the first production run. Manufacturers need this volume to justify the cosmetic chemist time, stability studies (typically a 3-month accelerated study at minimum, often a 6-month or 12-month real-time study for claim support), and regulatory documentation. Several factors push MOQs higher: complex emulsion systems, specialty packaging like airless pumps or glass droppers with tight tolerances, short fill windows in summer heat (TXA can be sensitive to thermal stress during manufacturing), and any claim requiring third-party testing such as ophthalmologist-tested or dermatologist-tested. Geography matters too. US-based manufacturers often have slightly higher MOQs than Asian co-packers (particularly South Korean or Chinese OEM factories), though the quality audit process for overseas partners is more involved. European manufacturers are competitive on quality but often have minimum batch weights rather than unit counts, which can translate to 500+ units depending on fill size. First-time founders commonly make the mistake of choosing the lowest possible MOQ without verifying the manufacturer's TXA experience. A low MOQ means little if the formula degrades within three months because the manufacturer lacked experience with TXA pH sensitivity. Always ask for stability data on TXA-containing products before committing. AJ Cosmo Labs lists vetted cosmetic manufacturers by MOQ range, so you can filter specifically for partners who work at the 100–500 unit scale without sifting through enterprise-only co-packers.

The total landed cost of a private label tranexamic acid niacinamide eye serum has several components, and founders frequently underestimate the non-fill costs. Breaking it down helps you budget accurately from the start. Formula development fees range from $0 for a white-label stock formula to $1,500–$5,000+ for a fully custom formula developed by a cosmetic chemist. Some manufacturers roll this cost into the per-unit price at scale; others charge it upfront as a non-refundable development fee. Always clarify whether you own the formula IP at the end of development — many manufacturers retain ownership unless you explicitly negotiate otherwise. Stability and safety testing costs $500–$2,500 depending on the test panel. At minimum you need a 3-month accelerated stability study (40°C/75% RH) and a preservative efficacy test (challenge test). For EU market entry you also need a Cosmetic Product Safety Report (CPSR) prepared by a qualified safety assessor, which typically costs $500–$1,500 per SKU. Fill and finish fees — the actual manufacturing cost — run approximately $4–$9 per unit at 100–300 units for a stock formula, $7–$14 per unit at 300–500 units for semi-custom, and $12–$22+ per unit for fully custom at sub-1,000 unit volumes. These fees cover raw materials (TXA and pharmaceutical-grade niacinamide are not cheap actives), compounding, filling, capping, and basic QC. Packaging adds $1.50–$6.00 per unit depending on your choice of glass dropper bottle, airless pump, or plastic tube, plus any secondary packaging like a folding carton. Label printing for short runs (100–500 units) on digital presses costs roughly $0.30–$0.80 per label. Shipping and logistics, import duties (if manufacturing overseas), and any third-party claim testing (ophthalmologist-tested typically requires a panel study costing $3,000–$8,000) are additional. All in, a founder launching a 300-unit white-label run with basic packaging might spend $3,500–$5,500 total. A 500-unit semi-custom launch with a glass dropper bottle and stability testing might run $8,000–$14,000. A full custom development at 1,000 units with claim testing can exceed $25,000 before you sell a single bottle. The most common budgeting mistake is treating the per-unit fill fee as the total cost. When you factor in development, testing, packaging, and logistics, the true cost per unit is often 2–3x the quoted fill fee — especially at low MOQs. Use AJ Cosmo Labs to request itemized quotes so every cost component is visible before you commit.

Timeline is one of the most frequently misjudged variables in a private label skincare launch, and tranexamic acid formulas have a few specific considerations that can extend the process. For a stock white-label formula — where the manufacturer already has a stable TXA-niacinamide base on the shelf — the process from signed agreement to finished goods typically runs 4–6 weeks. Most of that time is consumed by label design approval, packaging procurement, and fill scheduling rather than formulation. This is the fastest path to market and the best option for founders testing demand before investing in a custom formula. Semi-custom development (adjusting active levels, swapping a preservative, or modifying viscosity in an existing base) adds a formulation and re-stability phase. Expect 8–12 weeks: 2–3 weeks for the lab to revise and produce samples, 1–2 weeks for your review and feedback cycle, and 4–6 weeks for an accelerated stability check on the modified formula before production. Some manufacturers will allow provisional production release with stability studies still running, which can save 4–6 weeks — ask about this explicitly. Fully custom formula development is the longest path. The typical sequence: brief submission and kickoff (1–2 weeks), initial prototype development (3–6 weeks), sample review and revision rounds (2–6 weeks depending on how many iterations are needed), accelerated stability study (12 weeks minimum for a full accelerated panel, though a preliminary 4-week read can unlock provisional production), challenge testing (4 weeks), label compliance review (1–2 weeks), and production fill (2–4 weeks). Total: 14–24 weeks in a realistic scenario, occasionally longer if early prototypes miss the mark on TXA stability. TXA is specifically worth flagging because it requires the formula to be maintained at pH 4.5–6.0 for optimal stability. If a cosmetic chemist isn't experienced with TXA, early prototypes may come back with pH drift or yellowish discoloration during the stability study — triggering additional development rounds and adding 4–8 weeks. Seasonal production scheduling at the manufacturer also affects timeline. Summer months are often congested for skincare fills, and Q4 slots book out early. Build buffer into your timeline. The most common mistake founders make is briefing a manufacturer in, say, March expecting a May launch, without accounting for sampling rounds and stability. A realistic launch date for a custom eye serum briefed in March is September at the earliest. AJ Cosmo Labs lets you post your brief with a target launch date so manufacturers self-select based on production availability — saving weeks of back-and-forth.

The effective and safe concentration ranges for both ingredients in an eye serum are well-studied, and your cosmetic chemist should formulate within established parameters while also meeting your efficacy and claim goals. Transexamic acid in topical cosmetics is typically used at 2–5% by weight. Most clinical studies demonstrating brightening efficacy around the periorbital area have used concentrations in the 2–3% range. Going above 5% offers diminishing returns in cosmetic applications and may increase the risk of tingling or mild irritation on the delicate eye area skin, which is thinner than facial skin (approximately 0.5 mm vs. 2 mm). Some Korean OEM formulas use TXA as low as 1% in combination with other brightening agents, relying on synergy rather than TXA alone. Niacinamide in eye formulas is most commonly used at 2–5%. The 5% concentration has the strongest published evidence for reducing melanosome transfer and improving skin barrier function. Higher concentrations (above 5%) are used in some face serums, but around the eye, higher niacinamide can occasionally cause flushing or mild irritation in sensitive individuals — particularly if formulated at higher pH where niacinamide can convert to niacin. Your cosmetic chemist should buffer the formula and conduct a human repeat insult patch test (HRIPT) if you're using 5%+. The combination of TXA and niacinamide is additive in its brightening mechanism: TXA inhibits plasminogen activator upstream of pigment synthesis while niacinamide blocks melanosome transfer downstream — meaning they act on different steps of the same pathway. This synergy means you can achieve meaningful brightening results at the lower end of each ingredient's range, which is relevant for cost management (both are mid-to-premium cost actives) and for tolerability claims. Formulation pH is critical: TXA is most stable at pH 4.5–6.0, and niacinamide is most stable below pH 6.0. Keeping the formula within pH 5.0–5.5 satisfies both active stability requirements and is compatible with the skin's natural acid mantle. Common supporting ingredients in this serum type include caffeine (de-puffing via vasodilation), hyaluronic acid (hydration and plumping), peptides like Matrixyl or Argireline (for fine line appearance), and allantoin (soothing). Ask your manufacturer's cosmetic chemist to walk you through how each supporting ingredient was selected relative to the TXA-niacinamide backbone. When briefing manufacturers on the AJ Cosmo Labs platform, specify your target TXA and niacinamide percentages upfront — this filters out formulators who only work with lower actives concentrations and saves significant time.

Eye serums sold as cosmetics — not drugs — are regulated under different frameworks in the US and EU, and both have tightened their requirements in recent years. Understanding both is essential if you plan to sell internationally. In the United States, topical eye serums are regulated by the FDA as cosmetics under the Federal Food, Drug, and Cosmetic Act. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly updated US cosmetic compliance requirements. Key obligations now include: facility registration for manufacturers and packers (due annually), product listing with the FDA (required for products marketed in the US), good manufacturing practice compliance (FDA is developing formal GMP regulations), serious adverse event reporting to the FDA within 15 days, and safety substantiation — you must be able to demonstrate that your product is safe for its intended use, which in practice means you need stability data, a challenge test, and ideally a dermatologist or ophthalmologist safety review for a product used near the eye. Claims matter enormously in the US. If you claim the serum "treats" dark circles, reduces puffiness caused by a medical condition, or otherwise crosses into drug territory, FDA may classify it as an over-the-counter drug — triggering a far more burdensome approval pathway. Stick to cosmetic claim language: "visibly brightens," "reduces the appearance of dark circles," "supports a more rested look." Transexamic acid is not currently restricted under US FDA cosmetic regulations — it is permitted in cosmetics as a skin-conditioning agent. Verify the current status with your cosmetic chemist as regulatory landscapes evolve. In the European Union, cosmetics are governed by EC Regulation No 1223/2009. Requirements include: a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor before market entry, product information file (PIF) maintained for 10 years, notification via the CPNP (Cosmetics Products Notification Portal) before placing on the market, responsible person designation (a legal EU entity), and ingredient restrictions per Annex II, III, IV, V, and VI of the regulation. TXA is not listed as a restricted ingredient under current EU annexes, but it is your safety assessor's responsibility to confirm safe use levels for periorbital application. For both markets, ensure your INCI labeling is correct and complete. All ingredients must be listed on the label in descending order of concentration, using INCI nomenclature. For a 10 mL or 15 mL eye serum, label real estate is tight — work with a regulatory consultant early to ensure compliance without sacrificing design. AJ Cosmo Labs connects founders with manufacturers who are experienced in both MoCRA compliance and EU dossier preparation, so you can vet partners on regulatory capability, not just fill capacity.

Finding a legitimate, GMP-certified contract manufacturer willing to work at low MOQs for an actives-forward eye serum is one of the most common challenges indie founders face. The issue is not that low-MOQ manufacturers don't exist — it's that they are hard to find through traditional channels and even harder to vet remotely. Start by defining your non-negotiables before you search: minimum MOQ you can afford, target formula type (stock vs. semi-custom vs. custom), required certifications (ISO 22716, NSF, Leaping Bunny, EWG Verified — whatever aligns with your brand), geography preference, and your timeline. Manufacturers who can't meet these criteria on paper should be filtered out immediately — don't waste sampling time on the wrong partner. When evaluating a shortlist, request the following documentation before signing anything: current ISO 22716 or equivalent GMP certificate, sample COAs (certificates of analysis) from recent TXA or niacinamide-containing batches, a reference client list or case studies (some manufacturers can't share client names but can describe product types), their stability study protocol, and their template manufacturing agreement so you can assess IP and exclusivity terms before your attorney reviews. Red flags that disqualify a manufacturer regardless of MOQ or price: inability to produce any stability data on similar formulas, unwillingness to provide INCI lists for review before signing, no clear answer on who owns the formula IP, no MoCRA facility registration (for US manufacturers post-2024), and excessive payment upfront (50%+ deposit before samples is a warning sign). Regional sourcing decisions carry real trade-offs. US manufacturers offer easier communication, faster shipping, and simpler regulatory alignment but often have higher per-unit costs and sometimes higher MOQs. Korean OEM factories offer world-class actives expertise (TXA-niacinamide combinations are very common in K-beauty contract manufacturing) and competitive pricing, but require a sourcing agent or strong English-language capability and add lead time for international shipping. Chinese OEM factories can offer the lowest MOQs and prices but require the most rigorous audit process. AJ Cosmo Labs was built to solve exactly this sourcing problem. The iOS app lets you post a product brief describing your formula, target active concentrations, MOQ, and timeline, and receive proposals from manufacturers who are already on the platform and vetted for cosmetics experience. You can message formulators directly, compare quotes side by side, track sample shipments, and make milestone payments through an escrowed system — all without cold email chains or trade show travel. Download the AJ Cosmo Labs app from the App Store to post your first brief and start receiving manufacturer proposals within days.

Yes — a white-label tranexamic acid niacinamide eye serum is the fastest path to a branded product on the market, and for founders who need to validate demand before investing in custom development, it is often the strategically correct choice. The white-label model means the manufacturer already has a finished, stability-tested formula on hand. You are applying your brand name, logo, and label to an existing product. Most white-label eye serums in this category have been through accelerated stability testing and a challenge test, meaning the core safety and performance work is already done. Your role is to select the formula from the manufacturer's catalog, choose a packaging option (they usually offer 2–5 SKU sizes and container types), design your label to their specification, and place your order. Timelines for white-label are 4–6 weeks in most cases. The first 1–2 weeks involve label artwork approval (your graphic designer produces a file meeting the manufacturer's print specs, typically a vector PDF). Week 2–3 covers label printing lead time if the manufacturer uses a third-party label printer. Weeks 3–5 are the fill, capping, labeling, and QC pass at the factory. Week 5–6 is shipping and delivery. Some US-based manufacturers with in-house digital label printing can compress this to 3 weeks for small runs. The trade-off with white-label is differentiation. Your formula will be identical (or nearly identical) to other brands sourcing from the same manufacturer. For a commodity-competitive space this matters; for founders launching into a specific niche channel (a spa retail program, an esthetician's treatment menu, a subscription box) where the brand story matters more than formula exclusivity, white-label is a perfectly defensible strategy. To bridge the gap, some manufacturers offer "semi-exclusive" white-label arrangements where they agree not to sell the identical formula to competitors in your distribution channel — ask about channel exclusivity even if full formula exclusivity isn't on the table. When comparing white-label options, look at the TXA and niacinamide percentages in the existing formula (the manufacturer should provide a full INCI list), the packaging options available, whether the formula has been tested for periorbital use specifically (not just face serum use), and what labeling claims are pre-approved by the manufacturer's safety assessor. AJ Cosmo Labs lists manufacturers who offer stock white-label eye serum bases ready for branding at 100-unit minimums. Use the iOS app to filter by product type and MOQ, view what stock formulas are available, and message manufacturers directly to request a sample before committing to a production run.